Novo Nordisk shares in Copenhagen finally caught a bid after the U.S. Food and Drug Administration issued 30 warning letters to telehealth companies for making false and misleading claims regarding compounded GLP-1 products (otherwise known as copycat GLP-1s) offered on their websites. FDA has warned 30 telehealth companies about misleading drug ads. Consumers should not be fooled into thinking that unapproved, compounded GLP-1 drugs—marketed by telehealth companies—are generic versions or the same as FDA-approved products. — Dr. Marty Makary (@DrMakaryFDA) March 3, 2026 Citi analyst Geoff Meacham told clients that a quick scan of some of the warning letters “shows the agency is taking issue with telehealth companies calling their compounded products’ generic Zepbound’ or ‘generic Mounjaro’ when these products are not FDA-approved.” “It’s a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms—and taking swift action,” FDA Commissioner Marty Makary wrote in a statement. Makary noted, “Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not …